What is the purpose of this trial?
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Southwest Oncology Group (SWOG)
Start Date: 03/20/2019
End Date: 02/01/2022
Last Updated: 03/21/2019
Study HIC#: 2000022373